The Oxford Biotech Podcast

Medical cannabis is expected to reach 56.7B market value by 2026. On this episode we hear from Oxford Cannabinoid Technologies co-founders Neil Mahapatra (Kingsley Capital Partners, Rothschild, Morgan Stanley) and Gavin Sathianathan (Alta Flora, Facebook, Bain) about their use of technological advances and a network innovation model to develop patient-saving pharmaceuticals from cannabis.

 Music from: https://freesound.org/ 

 OCT: https://www.oxcantech.com/

Reverse Moore's Law: drug discovery gets more expensive every year. On the Oxford Biotech Podcast we talk to Professor Chas Bountra, former head of biology at GSK, about the new open-source solution he is developing to bring down the costs of lead development.

Music from: https://freesound.org/

Two colleagues began engineering RNA-guided nucleases before CRISPR-Cas9 was ever used for gene editing. We visited them in Israel to learn about their startup, the booming gene editing industry, and how they might just beat CRISPR at its own game. 

Yoel: linkedin.com/in/yoelshiboleth

Music from: https://freesound.org/

Prof Kiana Aran walks us through the invention and applications of CRISPR-Chip - her celebrated invention that enables sequence-specific real-time detection of DNA without amplification or complex sample processing. 

CRISPR-Chip: https://www.nanosens.com/crispr-chip   

Music from: https://freesound.org/

Why the algae biofuels bubble burst and what comes next; the future directions of strain engineering; reflections on starting an early stage plant science biotech. 

  Robert's Lab: http://jinkersonlab.engr.ucr.edu/

  Music from: https://freesound.org/

The biochemical secrets to spider silk's strength; producing artificial spider's silk using synthetic biology; why Bolt chose apparel - and their plan to translate science into sales; how to win The Bay Area Top Workplace Award three years in a row!

Bolt Thread's website: https://boltthreads.com/

Music from: https://freesound.org/

The emerging technology of graphene biosensors; Cardea's commercialisation strategy that enabled it to succeed in nano where decades of industry attempts had failed; what the San Diego biotech ecosystem offers that is attracting biotech entrepreneurs vs Boston and The Bay?

Cardea's website: https://www.cardeabio.com/

Music from: https://freesound.org/